<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0607210851
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rosalus 20mg Film coated Tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        87.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GULF PHARMACEUTICAL INDUSTIRES- JULPHAR" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GULF PHARMACEUTICAL INDUSTIRES- JULPHAR
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GULF PHARMACEUTICAL INDUSTIRES- JULPHAR
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>ROSALUS</strong> belongs to a group of medicines called statins.</p><p><strong>You have been prescribed ROSALUS because:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; You have a high cholesterol level. This means you are at risk from a heart attack or stroke. <strong>ROSALUS</strong> is used in adults, adolescents and children 6 years or older to treat high cholesterol.</p><p>You have been advised to take a statin, because changing your diet and doing more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking <strong>ROSALUS</strong>.</p><p>Or</p><p>&bull;&nbsp;&nbsp;&nbsp; You have other factors that increase your risk of having a heart attack, stroke or related health problems.</p><p>Heart attack, stroke and other problems can be caused by a disease called atherosclerosis.</p><p>Atherosclerosis is due to buildup of fatty deposits in your arteries.</p><p><strong>Why it is important to keep taking ROSALUS?</strong></p><p><strong>ROSALUS</strong> is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.</p><p>There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C).</p><p>&bull;&nbsp;&nbsp;&nbsp; <strong>ROSALUS</strong> can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.</p><p>&bull;&nbsp;&nbsp;&nbsp; It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood.</p><p>For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.</p><p>Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems.</p><p>You need to&nbsp;<strong>keep taking ROSALUS</strong>, even if it has got your cholesterol to the right level, because&nbsp;<strong>it prevents your cholesterol levels from creeping up again</strong>&nbsp;and causing buildup of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Do not take Rosalus</u></strong><strong>:</strong></p><p>&bull;&nbsp; <strong>If you have ever had an allergic reaction to Rosuvastatin,</strong>&nbsp;or to any of its ingredients.</p><p>&bull;&nbsp; <strong>If you are pregnant</strong>&nbsp;or breast-feeding. If you become pregnant while taking <strong>ROSALUS stop taking it immediately and tell your doctor</strong>. Women should avoid becoming pregnant while taking <strong>ROSALUS</strong> by using suitable contraception.</p><p>&bull;&nbsp; <strong>If you have liver disease.</strong></p><p>&bull;&nbsp; <strong>If you have severe kidney problems.</strong></p><p>&bull;&nbsp; <strong>If you have repeated or unexplained muscle aches or pains.</strong></p><p>&bull;&nbsp; <strong>If you take a drug combination of sofosbuvir/velpatasvir/voxilaprevir</strong> (used for viral infection of the liver called hepatitis C).</p><p>&bull;&nbsp; <strong>If you take a drug called ciclosporin</strong>&nbsp;(used, for example, after organ transplants)</p><p>If any of the above applies to you (or you are in doubt),&nbsp;<strong>please go back and see your doctor</strong>.</p><p><strong>In addition, do not take Rosuvastatin 40 mg (the highest dose):</strong></p><p>&bull;&nbsp; <strong>If you have moderate kidney problems</strong>&nbsp;(if in doubt, please ask your doctor).</p><p>&bull;&nbsp; <strong>If your thyroid gland</strong>&nbsp;is not working properly.</p><p>&bull;&nbsp; <strong>If you have had any repeated or unexplained muscle aches or pains</strong>, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.</p><p>&bull;&nbsp; <strong>If you regularly drink large amounts of alcohol.</strong></p><p>&bull;&nbsp; <strong>If you are of Asian origin</strong>&nbsp;(Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull;&nbsp; <strong>If you take other medicines called fibrates</strong>&nbsp;to lower your cholesterol.</p><p>If any of the above applies to you (or you are in doubt),&nbsp;<strong>please go back and see your doctor</strong>.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking <strong>ROSALUS</strong>.</p><p>&bull;&nbsp; <strong>If you have problems with your kidneys.</strong></p><p>&bull;&nbsp; <strong>If you have problems with your liver.</strong></p><p>&bull;&nbsp; <strong>If you have had repeated or unexplained muscle aches or pains</strong>, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness that is constant.</p><p>&bull;&nbsp; <strong>If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking ROSALUS</strong> <strong>or other related medicines.</strong></p><p>&bull;&nbsp; <strong>If you regularly drink large amounts of alcohol.</strong></p><p>&bull;&nbsp; <strong>If your thyroid gland</strong>&nbsp;is not working properly.</p><p>&bull;&nbsp; <strong>If you take other medicines called fibrates</strong>&nbsp;to lower your cholesterol. Please read this leaflet carefully, even if you have taken other medicines for high cholesterol before.</p><p>&bull;&nbsp; <strong>If you take medicines used to treat the HIV infection</strong>&nbsp;e.g. ritonavir with lopinavir and/or atazanavir, please see <strong>Other medicines and ROSALUS</strong>.</p><p>&bull;&nbsp; <strong>If you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for bacterial infection), orally or by injection. The combination of fusidic acid and ROSALUS</strong> <strong>can lead to serious muscle problems (rhabdomyolysis), please see &ldquo;Other medicines and ROSALUS&rdquo;.</strong></p><p>&bull;&nbsp; <strong>If you are over 70</strong>&nbsp;(as your doctor needs to choose the right start dose of <strong>ROSALUS</strong> to suit you)</p><p>&bull;&nbsp; <strong>If you have severe respiratory failure</strong>.</p><p>&bull;&nbsp; <strong>If you are of Asian origin</strong>&nbsp;&ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of <strong>ROSALUS</strong> to suit you.</p><p>If any of the above applies to you (or if you are not sure):</p><p>&bull;&nbsp; <strong>Do not take Rosuvastatin 40 mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of ROSALUS.</strong></p><p>Serious skin reactions including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with <strong>ROSALUS</strong> treatment. Stop using <strong>ROSALUS</strong> and seek medical attention immediately if you notice any of the symptoms described in Section 4 &ldquo;Possible side effects&rdquo;.</p><p>In a small number of people, statins can affect the liver. This is identified by a simple test which looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) before and during treatment with <strong>ROSALUS</strong>.</p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p><strong>Children and adolescents</strong></p><p>&bull;&nbsp; <strong>If the patient is under 6 years old:</strong>&nbsp;<strong>ROSALUS</strong> should not be given to children younger than 6 years.</p><p>&bull;&nbsp; <strong>If the patient is below 18 years of age:</strong>&nbsp;The Rosuvastatin 40 mg is not suitable for use in children and adolescents below 18 years of age.</p><p><strong><u>Other medicines and ROSALUS</u></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines</p><p>Tell your doctor if you are taking any of the following:</p><p>&bull;&nbsp; ciclosporin (used for example, after organ transplants),</p><p>&bull;&nbsp; warfarin, clopidogrel or ticagrelor (or any other drug used for thinning the blood),</p><p>&bull;&nbsp; fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as ezetimibe),</p><p>&bull;&nbsp; indigestion remedies (used to neutralise acid in your stomach),</p><p>&bull;&nbsp; erythromycin (an antibiotic), fusidic acid (an antibiotic &ndash; please see Warnings and precautions),</p><p>&bull;&nbsp; an oral contraceptive (the pill),</p><p>&bull;&nbsp; regorafenib (used to treat cancer),</p><p>&bull;&nbsp; darolutamide (used to treat cancer),</p><p>&bull;&nbsp; capmatinib (used to treat cancer),</p><p>&bull;&nbsp; hormone replacement therapy,</p><p>&bull;&nbsp; fostamatinib (used to treat low platelet counts),</p><p>&bull;&nbsp; febuxostat (used to treat and prevent high blood levels of uric acid),</p><p>&bull;&nbsp; teriflunomide (used to treat multiple sclerosis),</p><p>&bull;&nbsp; any of the following drugs used to treat viral infections, including HIV or hepatitis C infection, alone or in combination (please see Warnings and precautions): ritonavir, lopinavir, atazanavir, sofosbuvir, voxilaprevir, ombitasvir, paritaprevir, dasabuvir, velpatasvir, grazoprevir, elbasvir, glecaprevir, pibrentasvir.</p><p>The effects of these medicines could be changed by <strong>ROSALUS</strong> or they could change the effect of <strong>ROSALUS</strong>.</p><p><strong>If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart ROSALUS. Taking ROSALUS with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in Section 4 &ldquo;Possible side effects&rdquo;.</strong></p><p><strong><u>Pregnancy and breast-feeding</u></strong></p><p><strong>Do not take ROSALUS</strong>&nbsp;if you are pregnant or breast-feeding. If you become pregnant while taking <strong>ROSALUS stop taking it immediately</strong>&nbsp;and tell your doctor. Women should avoid becoming pregnant while taking <strong>ROSALUS</strong> by using suitable contraception.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong><u>Driving and using machines</u></strong></p><p>Most people can drive a car and operate machinery while using Rosuvastatin<strong> </strong>&ndash; it will not affect their ability. However, some people feel dizzy during treatment with Rosuvastatin. If you feel dizzy, consult your doctor before attempting to drive or use machines.</p><p><strong><u>Important information about some of the ingredients of ROSALUS:</u></strong></p><p><strong>ROSALUS</strong> contains lactose.</p><p>If you have been told by your doctor that you have an intolerance to some sugars (lactose or milk sugar), contact your doctor before taking <strong>ROSALUS</strong>.</p><p>For a full list of ingredients please see&nbsp;<strong>section 6 &ldquo;Further information&rdquo;.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Usual doses in adults</strong></p><p><strong>If you are taking ROSALUS for high cholesterol:</strong></p><p><strong>Starting dose</strong></p><p>Your treatment with <strong>ROSALUS</strong> must start with the&nbsp;<strong>5 mg or the 10 mg dose</strong>, even if you have taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><p>&bull;&nbsp; Your cholesterol level.</p><p>&bull;&nbsp; The level of risk you have of experiencing a heart attack or stroke.</p><p>&bull;&nbsp; Whether you have a factor that may make you more sensitive to possible side effects.</p><p>Please check with your doctor or pharmacist which start dose of <strong>ROSALUS</strong> will best suit you.</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><p>&bull;&nbsp; You are of&nbsp;<strong>Asian origin</strong>&nbsp;(Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull;&nbsp; You are&nbsp;<strong>over 70 years</strong>&nbsp;of age.</p><p>&bull;&nbsp; You have moderate kidney problems.</p><p>&bull;&nbsp; You are at risk of muscle aches and pains (myopathy).</p><p><strong>Increasing the dose and maximum daily dose</strong></p><p>Your doctor may decide to increase your dose. This is so that you are taking the amount of <strong>ROSALUS</strong> that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, then 20 mg and then 40 mg if necessary. If you started on &nbsp;10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of four weeks between every dose adjustment.</p><p>The maximum daily dose of <strong>ROSALUS</strong> is 40 mg.</p><p>It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.</p><p><strong>If you are taking ROSALUS to reduce your risk of having a heart attack, stroke or related health problems:</strong></p><p>The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above.</p><p><strong>Use in children and adolescents aged 6-17 years </strong></p><p>The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once daily. The usual start dose is 5 mg per day, and your doctor may gradually increase your dose to find the right amount of <strong>ROSALUS</strong> for you. The maximum daily dose of <strong>ROSALUS </strong>is 10 or 20 mg for children aged 6 to 17 years depending on your underlying condition being treated. Take your dose once a day. Rosuvastatin <strong>40 mg</strong> tablet should <strong>not</strong> be used by children.</p><p><strong>Taking your tablets</strong></p><p>Swallow each tablet whole with a drink of water.</p><p><strong>Take ROSALUS once daily</strong>. You can take it at any time of the day with or without food.</p><p>Try to take your tablet at the same time every day to help you to remember it.</p><p><strong>Regular cholesterol checks</strong></p><p>It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level.</p><p>Your doctor may decide to increase your dose so that you are taking the amount of <strong>ROSALUS</strong> that is right for you.</p><p><strong>If you take more ROSALUS than you should</strong></p><p>Contact your doctor or nearest hospital for advice.</p><p>If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking <strong>ROSALUS</strong>.</p><p><strong>If you forget to take ROSALUS</strong></p><p>Don&rsquo;t worry; just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking ROSALUS</strong></p><p>Talk to your doctor if you want to stop taking <strong>ROSALUS</strong>. Your cholesterol levels might increase again if you stop taking <strong>ROSALUS</strong>.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>It is important that you are aware of what these side effects may be. They are usually mild and disappear after a short time.</p><p><strong>Stop taking ROSALUS and seek medical help immediately</strong>&nbsp;if you have any of the following allergic reactions:</p><p>&bull;&nbsp;&nbsp;&nbsp; Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p>&bull;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp; Severe itching of the skin (with raised lumps).</p><p>&bull;&nbsp;&nbsp;&nbsp; Reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome).</p><p>&bull;&nbsp;&nbsp;&nbsp; Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).</p><p><strong>Also, stop taking ROSALUS and talk to your doctor immediately: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp; <strong>If you have any unusual aches or pains</strong>&nbsp;in your muscles which go on for longer than you might expect. Muscle symptoms are more common in children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as&nbsp;<em>rhabdomyolysis</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp; <strong>If you experience muscle rupture.</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; <strong>If you have lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).</strong></p><p><strong>Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients):</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Headache, stomach pain, constipation, feeling sick, muscle pain, feeling weak, dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your medicine (only 40 mg)</p><p>&bull;&nbsp;&nbsp;&nbsp; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p><strong>Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients):</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Rash, itching or other skin reactions</p><p>&bull;&nbsp;&nbsp;&nbsp; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your medicine (only 5 mg, 10 mg and 20 mg).</p><p><strong>Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients):</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps).&nbsp;<strong>If you think you are having an allergic reaction, then stop taking ROSALUS</strong> and seek medical help immediately</p><p>&bull;&nbsp;&nbsp;&nbsp; Muscle damage in adults &ndash; as a precaution,&nbsp;<strong>stop taking ROSALUS and talk to your doctor immediately if you have any unusual aches or pains</strong>&nbsp;in your muscles which go on for longer than expected</p><p>&bull;&nbsp;&nbsp;&nbsp; A severe stomach pain (inflamed pancreas)</p><p>&bull;&nbsp;&nbsp;&nbsp; Increase in liver enzymes in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp; Bleeding or bruising more easily than normal due to low level of blood platelets.</p><p>&bull;&nbsp;&nbsp;&nbsp; Lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).</p><p><strong>Very rare possible side effects (these may affect less than 1 in 10,000 patients):</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Jaundice (yellowing of the skin and eyes), hepatitis (an inflamed liver), traces of blood in your urine, damage to the nerves of your legs and arms (such as numbness), joint pain, memory loss, breast enlargement in men (gynaecomastia).</p><p><strong>Side effects of unknown frequency may include:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Diarrhoea (loose stools), cough, shortness of breath, oedema (swelling), sleep disturbances, including insomnia and nightmares, sexual difficulties, depression, breathing problems, including persistent cough and/or shortness of breath or fever, tendon injury, muscle weakness that is constant</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p>-&nbsp;&nbsp; <strong>Fax</strong><strong>: </strong>+966-11-205-7662</p><p>-&nbsp;&nbsp; <strong>SFDA Call Centre:</strong> 19999</p><p>-&nbsp;&nbsp; <strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; <strong>Website: </strong>https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>-&nbsp;&nbsp; Please contact the relevant competent authority</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp; Do not use <strong>ROSALUS</strong> after the expiry date (EXP) which is stated on the blister strip and the carton. The expiry date refers to the last day of that month.</p><p>-&nbsp; Store below 30<sup>o</sup>C.</p><p>-&nbsp; Do not throw away any medicines via waste-water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance in ROSALUS is Rosuvastatin. </strong></p><p><strong>Each film-coated tablet contains: </strong>Rosuvastatin<strong> </strong>(as<strong> </strong>Rosuvastatin calcium) 5 mg, 10 mg or 20 mg.<strong> </strong></p><p><strong>Other ingredients are:</strong> Tribasic calcium phosphate, lactose, microcrystalline cellulose, crospovidone, magnesium stearate, hypromellose, triacetin, titanium dioxide and iron oxide red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ROSALUS 5 mg, 10 mg or 20 mg film-coated tablets are available in packs of 28 tablets each (4 blisters of 7 tablets each) and in packs of 56 tablets each (8 blisters of 7 tablets each).   
* Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot;Julphar&quot;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/02/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي <strong>روزالِّس </strong>&nbsp;إلى مجموعة من الأدوية تعرف باسم الستاتين.</p><p dir="RTL"><strong>لقد وصف لك طبيبك المعالج تناول روزالِّس لأحد الأسباب التالية:</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong>&nbsp;إذا كنت تعاني من ارتفاع مستوى الكوليستيرول. مما يعني أنك عرضة لخطر الإصابة بالنوبة القلبية أو السكتة الدماغية. يستخدم <strong>روزالِّس </strong>في فئة البالغين، المراهقين والأطفال بعمر 6 سنوات وما فوق لعلاج ارتفاع مستويات كوليستيرول الدم.</p><p dir="RTL">لقد نصحك طبيبك بتناول الأدوية من مجموعة الستاتين، لأن تغيير نظامك الغذائي، وممارسة التمارين الرياضية أصبح أمراً غير كافي لتصحيح مستويات الكوليستيرول. يجب عليك الاستمرار في ممارسة التمارين الرياضية و اتباع نظام غذائي منخفض الكوليستيرول أثناء تناول <strong>روزالِّس </strong>.</p><p dir="RTL">أو</p><p dir="RTL"><strong>&bull;&nbsp; </strong>إذا كنت تعاني من وجود عوامل أخرى قد تزيد من خطر إصابتك بالنوبة القلبية والسكتة الدماغية ، أو غيرها من المسببات المرضية الأخرى ذات العلاقة بالقلب والأوعية الدموية.</p><p dir="RTL">إن النوبة القلبية والسكتة الدماغية وغيرها من المشاكل قد تنجم عن مرض يعرف باسم تصلب الشرايين.</p><p dir="RTL">إن تصلب الشرايين يحدث نتيجة لتراكم الرواسب الدهنية في الشرايين.</p><p dir="RTL"><strong>ماهي أهمية الاستمرار في تناول روزالِّس ؟</strong></p><p dir="RTL">يستخدم <strong>روزالِّس </strong>&nbsp;لتصحيح مستويات المواد الدهنية في الدم والتي تعرف باسم الليبيدات، ويعد الكوليستيرول هو الأكثر شيوعاً.</p><p dir="RTL">يوجد أنواع مختلفة من الكوليستيرول في الدم &ndash; الكوليستيرول منخفض الكثافة (الضار) &ndash; والكوليستيرول عالي الكثافة (النافع).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>يقلل <strong>روزالِّس </strong>&nbsp;من الكوليستيرول منخفض الكثافة (الضار) ويزيد من الكوليستيرول عالي الكثافة (النافع).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>&nbsp;يساعد <strong>روزالِّس </strong>&nbsp;الجسم على منع إنتاج الكوليستيرول منخفض الكثافة (الضار)، كما أنه يحسن من قدرة الجسم على إزالته من الدم.</p><p dir="RTL">إن معظم الأشخاص لا يشعرون بارتفاع مستويات الكوليستيرول، حيث أن ارتفاع مستويات الكوليستيرول لا يؤثر عليهم ولا تنتج عنه أية أعراض.</p><p dir="RTL">ولكن على الرغم من ذلك، إذا ترك الأمر دون الخضوع للعلاج، فقد يؤدي ذلك إلى تراكم الرواسب الدهنية على جدران الأوعية الدموية، مما يتسبب في تضييقها.</p><p dir="RTL">في بعض الأحيان، قد يحدث انسداد في مجرى الأوعية الدموية التي ضاقت نتيجة لتراكم الرواسب الدهنية على جدرانها الأمر الذي يؤدي إلى انقطاع جريان وتدفق الدم إلى القلب أو الدماغ مما يؤدي إلى الإصابة بالنوبة القلبية أو السكتة الدماغية. يمكنك الحد من خطر الإصابة بالنوبة القلبية أو السكتة الدماغية أو غيرها من المسببات المرضية الأخرى ذات العلاقة بالقلب والأوعية الدموية عن طريق خفض مستويات الكوليستيرول.</p><p dir="RTL">كما أنك بحاجة إلى <strong>الاستمرار في تناول</strong> <strong>روزالِّس</strong>، حتى وإن أصبحت مستويات الكوليستيرول ضمن معدلاتها الطبيعية الصحيحة، يعد <strong>روزالِّس</strong> قادراً على <strong>منع معاودة ارتفاع مستويات</strong> <strong>الكوليستيرول مرة أخرى </strong>والتي تتسبب في تراكم الرواسب الدهنية. ومع ذلك، يجب عليك التوقف عن تناول هذا الدواء إذا ما أخبرك طبيبك المعالج بهذا، أو إذا أصبحت حاملاً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>يجب عليك عدم تناول روزالِّس &nbsp;في الحالات التالية:</u></strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا عانيت مسبقاً من تفاعلات تحسسية تجاه روسوفاستاتين، </strong>أو أي من المواد الغير فعالة الأخرى في هذا الدواء.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت حاملاً </strong>أو<strong> </strong>ترضعين طفلك رضاعة طبيعية<strong>.</strong> إذا أصبحت حاملاً أثناء فترة العلاج باستخدام <strong>روزالِّس، توقفي عن تناوله على الفور واخبري طبيبك المعالج بذلك</strong>.</p><p dir="RTL">يجب على النساء تجنب حدوث الحمل أثناء تناول <strong>روزالِّس </strong>عن طريق استخدام أحد وسائل منع الحمل المناسبة.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من أمراض في الكبد.</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من مشاكل حادة في الكلى. </strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من آلام متكررة أو غير معروفة السبب في العضلات.</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتناول مجموعة دوائية من سوفوسبوفير / فيلاتاسفير / فوكسيلابريفير</strong> (يستخدم لعلاج العدوى بفيروس الالتهاب الكبدي الوبائي فيروس سي).</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتناول مادة دوائية تعرف باسم سيكلوسبورين</strong> (يستخدم على سبيل المثال عقب الخضوع لجراحة زراعة الأعضاء).</p><p dir="RTL">إذا كان أي مما سبق ذكره ينطبق عليك، أو إذا كنت لست متأكداً من ذلك، <strong>فيرجى منك </strong><strong>إخبار طبيبك المعالج</strong>.</p><p dir="RTL"><strong>بالإضافة إلى ذلك، يجب عليك عدم تناول روسوفاستاتين 40 ملغم (أقصى مقدار للجرعة) في الحالات التالية:</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من مشاكل في الكلى متوسطة الشدة</strong> (إذا كنت لست متأكداً من ذلك، يرجى منك استشارة طبيبك المعالج)</p><p dir="RTL"><strong>&bull;&nbsp; </strong>إذا كنت تعاني من&nbsp; اضطراب في <strong>وظائف الغدة الدرقية</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من آلام متكررة أو مجهولة السبب في العضلات،</strong> لديك تاريخ شخصي أو عائلي مسبق من الإصابة بمشاكل في العضلات، أو تاريخ سابق من حدوث مشاكل في العضلات أثناء تناول أي من الأدوية الأخرى الخافضة لمستويات الكوليستيرول.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتعاطى كميات كبيرة من الكحول بصورة دائمة.</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت من أصول آسيوية</strong> (والتي تشمل اليابان، الصين، الفلبين، فيتنام، كوريا والهند)</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتناول أية أدوية أخرى</strong> <strong>تعرف باسم الفايبرات </strong>لخفض مستويات الكوليستيرول.</p><p dir="RTL">إذا كان أي مما سبق ذكره ينطبق عليك، أو إذا كنت لست متأكداً من ذلك،<strong> يرجى منك إخبار طبيبك المعالج.</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل أن تتناول <strong>روزالِّس </strong>&nbsp;في الحالات التالية:</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من مشاكل في الكلى</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من مشاكل في الكبد</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من آلام متكررة أو مجهولة السبب في العضلات،</strong> لديك تاريخ شخصي أو عائلي مسبق من الإصابة بمشاكل في العضلات، أو تاريخ سابق من حدوث مشاكل في العضلات أثناء تناول أي من الأدوية الأخرى الخافضة لمستويات الكوليستيرول. يرجى منك إخبار<strong> </strong>طبيبك على الفور إذا عانيت من آلام غير معروفة السبب في العضلات وبصورة خاصة في حال شعورك بالتوعك أو في حال تعرضك للحمى. كما يجب عليك إخبار<strong> </strong>طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تعاني من ضعف دائم في العضلات.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من طفح جلدي شديد أو تقشر في الجلد، تقرحات و/أو تقرحات في الفم بعد تناول روزالِّس أو أية أدوية أخرى</strong><strong> ذات صلة</strong><strong>.</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتعاطى كميات كبيرة من الكحول بصورة دائمة</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong>إذا كنت تعاني من&nbsp; اضطراب في <strong>وظائف الغدة الدرقية</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتناول أية أدوية أخرى تعرف باسم الفايبرات</strong> لخفض مستويات الكوليستيرول. يرجى منك قراءة هذه النشرة بعناية، حتى وإن كنت قد تناولت مسبقاً أية أدوية أخرى لإرتفاع الكوليستيرول في الدم.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتناول أية أدوية تستخدم لعلاج عدوى فيروس نقص المناعة البشرية المكتسبة</strong>، على سبيل المثال: ريتونافير مع لوبينافير و/ أو أتازانفير، يرجى منك الإطلاع على فقرة<br /><strong>تناول</strong><strong> الأدوية الاخرى و روزالِّس .</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تتناول أو تناولت في السبع أيام الماضية أحد الأدوية التي تعرف باسم حمض الفيوسيديك (دواء يستخدم في علاج حالات العدوى الفطرية) عن طريق الفم أو عن طريق الحقن. يمكن أن يؤدي الاستخدام المتزامن لكل من حمض الفيوسيديك و روزالِّس إلى مشاكل عضلية خطيرة (انحلال الربيدات)، يرجى منك الإطلاع على فقرة تناول</strong><strong> الأدوية الاخرى و روزالِّس.</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كان عمرك يتعدى 70</strong> <strong>سنة</strong> (حيث أن طبيبك المعالج بحاجة إلى اختيار الجرعة الابتدائية الصحيحة من <strong>روزالِّس و</strong>المناسبة لك)<strong> </strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كنت تعاني من فشل حاد في الجهاز التنفسي.</strong></p><p dir="RTL">&bull;&nbsp; <strong>إذا</strong> <strong>كنت من أصول آسيوية</strong> (والتي تشمل اليابان، الصين، الفلبين، فيتنام، كوريا والهند)، حيث أن طبيبك المعالج بحاجة إلى اختيار الجرعة الابتدائية الصحيحة من <strong>روزالِّس &nbsp;و</strong>المناسبة لك.</p><p dir="RTL">إذا كان أي مما سبق ذكره ينطبق عليك، أو إذا كنت لست متأكداً من ذلك:</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>لا تتناول </strong><strong>أقصى جرعة من روسوفاستاتين (40 ملغم)&nbsp; وتحقق مع طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل البدء في تناول أي جرعة من روزالِّس .</strong></p><p dir="RTL">كما تم الإبلاغ عن حدوث تفاعلات جلدية شديدة بما في ذلك متلازمة ستيفن جونسون و التفاعلات الدوائية المصحوبة بفرط الإيزينوفيلات والأعراض الجهازية عند تناول <strong>روزالِّس </strong>. يرجى منك التوقف عن تناول <strong>روزالِّس</strong> والتواصل مع طبيبك المعالج على الفور في حال لاحظت حدوث أي من الأعراض المذكورة في البند رقم 4 &quot;التأثيرات الجانبية المحتمل حدوثها&quot;.</p><p dir="RTL">قد تؤثر الأدوية من مجموعة الستاتين على الكبد لدى عدد قليل من الأشخاص. يتم تحديد ذلك عن طريق إجراء اختبار بسيط يتم الكشف من خلاله عن ارتفاع مستويات إنزيمات الكبد في الدم. ولهذا السبب، فإن طبيبك المعالج عادة ما سيجري لك اختبار الدم (اختبار وظائف الكبد) قبل وأثناء العلاج باستخدام <strong>روزالِّس </strong>.</p><p dir="RTL">إذا كنت تعاني من داء السكري أو إذا كنت عرضة لخطر الإصابة بداء السكري فسوف يقوم طبيبك المعالج بمراقبتك عن كثب أثناء تناول هذا الدواء.</p><p dir="RTL">من المرجح أن تكون أكثر عرضة لخطر الإصابة بداء السكري، إذا كنت تعاني من ارتفاع مستوى السكر والدهون في الدم، تعاني من زيادة الوزن، وارتفاع ضغط الدم.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كان عمر المريض أقل من 6 سنوات:</strong> يجب عدم إعطاء <strong>روزالِّس </strong>&nbsp;للأطفال الذين تقل أعمارهم عن 6 سنوات.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>إذا كان عمر المريض أقل من 18 سنة:</strong> إن روسوفاستاتين 40 ملغم ليس مناسباً للأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة.</p><p dir="RTL"><strong><u>تناول الأدوية الأخرى وروزالِّس :</u></strong></p><p dir="RTL">يرجى منك إخبار<strong> </strong>طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى. أخبر طبيبك المعالج إذا كنت تتناول أحد الأدوية التالية:</p><p dir="RTL"><strong>&bull;&nbsp; </strong>السيكلوسبورين (يستخدم على سبيل المثال عقب الخضوع لجراحة زراعة الأعضاء).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>الوارفارين، كلوبيدوجريل أو تيكاجريلور (أو أية أدوية أخرى تستخدم لترقيق الدم).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>فايبرات (على سبيل المثال جيمفبروزيل، فينوفايبرات) أو أي دواء آخر يستخدم لخفض مستويات الكوليستيرول (مثل إزيتيميب).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>الأدوية التي تستخدم لعلاج عسر الهضم (الأدوية التي تستخدم لمعادلة حمض المعدة).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>الإريثروميسين (مضاد حيوي)، حمض الفيوسيديك (مضاد حيوي - يرجى الإطلاع على تحذيرات واحتياطات).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>وسائل منع الحمل الفموية (حبوب منع الحمل).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>ريجورافينيب (يستخدم لعلاج السرطان)</p><p dir="RTL"><strong>&bull;&nbsp; </strong>دارولوتاميد (يستخدم لعلاج السرطان)</p><p dir="RTL"><strong>&bull;&nbsp; </strong>كاباتينيب (يستخدم لعلاج السرطان).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>العلاج بالهرمونات البديلة</p><p dir="RTL"><strong>&bull;&nbsp; </strong>فوستاماتينيب (يستخدم لعلاج انخفاض تعداد الصفائح الدموية).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>فيبوكسوستات (يستخدم لعلاج ومنع ارتفاع مستويات حمض اليوريك في الدم).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>تريفلونوميد (يستخدم لعلاج التصلب اللويحي).</p><p dir="RTL"><strong>&bull;&nbsp; </strong>أي من الأدوية التالية التي تستخدم لعلاج الالتهابات الفيروسية، بما في ذلك فيروس نقص المناعة البشرية المكتسبة أو الالتهاب الكبدي الوبائي فيروس سي، بمفردها أو مجتمعة (يرجى الاطلاع على التحذيرات والاحتياطات): ريتونافير، لوبينافير، أتازانافير، سوفوسبوفير، فوكسيلابريفير، أومبيتاسفير، باريتابريفير، داسابوفير، فيلباتاسفير، جرازوبريفير، إلباسفير، جليكابريفير، بيبرنتاسفير.</p><p dir="RTL">قد يؤثر <strong>روزالِّس </strong>على فعالية هذه الأدوية، أو قد تؤثر هذه الأدوية على فعالية <strong>روزالِّس .</strong></p><p dir="RTL"><strong>إذا كنت بحاجة إلى تناول حمض الفوسيديك عن طريق الفم لعلاج أحد حالات العدوى البكتيرية ، فسوف تكون بحاجة إلى التوقف مؤقتًا عن استخدام هذا الدواء. سيخبرك طبيبك المعالج بالوقت الملائم الذي يمكنك خلاله إعادة تناول </strong><strong>روزالِّس </strong><strong>بأمان. إن تناول </strong><strong>روزالِّس </strong><strong>بالتزامن مع حمض الفوسيديك نادراً ما قد يؤدي إلى ضعف العضلات أو آلام العضلات (انحلال الربيدات). للمزيد من المعلومات حول انحلال الربيدات يرجى </strong><strong>الإطلاع</strong><strong> على البند رقم 4 &quot;التأثيرات الجانبية المحتمل حدوثها&quot;.</strong></p><p dir="RTL"><strong><u>الحمل والرضاعة الطبيعية</u></strong></p><p dir="RTL"><strong>يجب عليك التوقف عن تناول روزالِّس </strong>إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية.<strong> توقفي عن تناول روزالِّس على الفور </strong>إذا أصبحت حاملاً أثناء فترة العلاج مع ضرورة إبلاغ طبيبك المعالج بذلك. يجب على النساء تجنب حدوث الحمل أثناء تناول <strong>روزالِّس </strong>عن طريق استخدام أحد وسائل منع الحمل المناسبة.</p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعاملين معه قبل الإقدام على تناول أية أدوية.</p><p dir="RTL"><strong><u>القيادة واستخدام الآلات </u></strong></p><p dir="RTL">معظم الأشخاص بإمكانهم قيادة السيارة وتشغيل الآلات أثناء فترة العلاج باستخدام روسوفاستاتين، حيث أنه لن يؤثر على قدراتهم. ومع ذلك فإن بعض الأشخاص قد يشعرون بالدوخة أثناء فترة العلاج باستخدام روسوفاستاتين. في حال الشعور بالدوخة، يرجى منك استشارة طبيبك المعالج قبل الإقدام على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong><u>معلومات هامة عن بعض مكونات روزالِّس </u></strong></p><p dir="RTL">يحتوي<strong> روزالِّس </strong>على اللاكتوز</p><p dir="RTL">إذا كان قد أخبرك طبيبك المعالج بأنك تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض السكريات (اللاكتوز أو سكر الحليب)، يرجى منك استشارة طبيبك المعالج قبل أن تتناول <strong>روزالِّس </strong>.</p><p dir="RTL">لمعرفة قائمة المكونات كاملة يرجى منك الإطلاع على <strong>البند رقم 6. &quot;معلومات إضافية&quot;</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تناول هذا الدواء دائماً بدقة وفقاً لتعليمات طبيبك المعالج. استشر طبيبك المعالج أو الصيدلي الذي تتعامل معه ما لم تكن متأكداً من طريقة الاستخدام.</p><p dir="RTL"><strong>الجرعات المعتادة للبالغين</strong></p><p dir="RTL"><strong>إ</strong><strong>ذا كنت تتناول </strong><strong>روزالِّس</strong><strong> </strong><strong>لارتفاع مستويات الكوليستيرول في الدم:</strong></p><p dir="RTL"><strong>الجرعة الابتدائية</strong></p><p dir="RTL">يجب بدء العلاج باستخدام <strong>روزالِّس </strong>بجرعة مقدارها <strong>5 ملغم أو 10ملغم</strong>، حتى وإن كنت قد تناولت مسبقاً جرعة عالية من أحد الأدوية الأخرى التي تنتمي إلى مجموعة الستاتين.</p><p dir="RTL">إن اختيار طبيبك المعالج لمقدار الجرعة الابتدائية المناسبة لك سوف يعتمد على ما يلي:</p><p dir="RTL">&bull;&nbsp; مستوى الكوليستيرول لديك</p><p dir="RTL">&bull;&nbsp; مدى خطورة تعرضك للإصابة بالنوبة القلبية والسكتة الدماغية.</p><p dir="RTL">&bull;&nbsp; وجود عوامل قد تجعلك أكثر حساسية لحدوث التأثيرات الجانبية.</p><p dir="RTL">يرجى منك التحدث إلى &nbsp;طبيبك المعالج أو الصيدلي الذي تتعامل معه لمعرفة مقدار الجرعة الابتدائية المناسبة لك من <strong>روزالِّس </strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر طبيبك المعالج إعطائك أقل جرعة (5 ملغم) في الحالات التالية:</p><p dir="RTL">&bull;&nbsp; إذا كنت من <strong>أصول آسيوية</strong> (اليابانية، الصينية، الفلبينية، الفيتنامية، الكورية والهندية).</p><p dir="RTL">&bull;&nbsp; إذا كان عمرك قد <strong>تجاوز 70 عاماً</strong>.</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من مشاكل متوسطة الشدة في الكلى.</p><p dir="RTL">&bull;&nbsp; إذا كنت معرض لخطر الإصابة بآلام العضلات (اعتلال العضلات)</p><p dir="RTL"><strong>زيادة الجرعة و الجرعة القصوى اليومية</strong></p><p dir="RTL">قد يقرر طبيبك المعالج زيادة مقدار الجرعة المعطاة لك. وهذا يعني أنك الآن تتناول الجرعة الصحيحة والمناسبة لك من <strong>روزالِّس </strong>. إذا كنت قد بدأت العلاج بتناول جرعة مقدارها 5 ملغم، فإن طبيبك المعالج قد يقرر مضاعفة الجرعة إلى 10 ملغم، ثم إلى 20 ملغم، ومن ثم إلى 40 ملغم في حال استدعى الأمر القيام بذلك.</p><p dir="RTL">إذا كنت قد بدأت العلاج بتناول جرعة مقدارها 10ملغم، فإن طبيبك المعالج قد يقرر مضاعفة الجرعة إلى 20 ملغم، ومن ثم إلى 40 ملغم في حال استدعى الأمر القيام بذلك. سيكون هناك فترة زمينة فاصلة مدتها 4 أسابيع ما بين المرات التي سيتم فيها تعديل مقدار الجرعة.</p><p dir="RTL">إن أقصى مقدار للجرعة اليومية من <strong>روزالِّس </strong>هو 40 ملغم.</p><p dir="RTL">يستخدم أقصى مقدار للجرعة اليومية للمرضى الذين يعانون من ارتفاع شديد في مستويات الكوليستيرول والذين يعانون من ارتفاع خطر الإصابة بالنوبات القلبية أو السكتة الدماغية ولا يتم خفض مستويات الكوليستيرول لديهم بصورة كافية عند تناول جرعة مقدارها 20 ملغم.</p><p dir="RTL"><strong>إذا كنت تتناول </strong><strong>روزالِّس &nbsp;للحد من خطر الإصابة بالنوبة القلبية، السكتة الدماغية أو للوقاية من المسببات المرضية الأخرى ذات العلاقة بالقلب والأوعية الدموية</strong><strong>: </strong></p><p dir="RTL">يبلغ مقدار الجرعة الموصى بها 20 ملغم يومياً. ومع ذلك، فقد يقرر طبيبك المعالج تناول جرعة أقل إذا كنت تعاني من أحد العوامل السابق ذكرها أعلاه.</p><p dir="RTL"><strong>الاستخدام في المراهقين و الأطفال الذين تتراوح أعمارهم ما بين 6 - 17 سنة:</strong></p><p dir="RTL">يتراوح مقدار الجرعة الموصى بها في الأطفال والمراهقين بعمر 6 إلى 17 سنة ما بين 5 إلى 20 ملغم مرة واحدة يومياً.</p><p dir="RTL">يبلغ مقدار الجرعة الابتدائية الاعتيادية 5 ملغم يومياً. وقد يقوم طبيبك المعالج بزيادة الجرعة تدريجياً حتى يتوصل إلى الجرعة الملائمة لك من <strong>روزالس</strong>.</p><p dir="RTL">يبلغ الحد الأقصى للجرعة&nbsp; اليومية من <strong>روزالِّس </strong>10 ملغم أو 20 ملغم للأطفال من سن 6 إلى 17 سنة وذلك وفقاً للحالة التي يتم علاجها.</p><p dir="RTL">يجب عليك تناول الجرعة الخاصة بك مرة واحدة يومياً.</p><p dir="RTL">يجب <strong>عدم</strong> تناول روسوفاستاتين <strong>40 ملغم</strong> من قبل الأطفال.</p><p dir="RTL"><strong>كيفية تناول الأقراص</strong></p><p dir="RTL">يتم بلع القرص كاملاً مع شرب الماء.</p><p dir="RTL"><strong>يتم تناول</strong> <strong>روزالِّس</strong> <strong>مرة واحدة يومياً</strong>. يمكنك تناوله في أي وقت من اليوم مع أو بدون تناول الطعام.</p><p dir="RTL">حاول أن تتناول جرعتك في نفس الوقت كل يوم حتى تتمكن من تذكر موعد تناول الدواء.</p><p dir="RTL"><strong>إجراء فحوصات منتظمة لقياس مستويات الكوليستيرول </strong></p><p dir="RTL">من الضروري مراجعة طبيبك المعالج لإجراء فحوصات منتظمة لقياس مستويات الكوليسيترول، للتأكد من أن مستويات الكوليستيرول لديك قد أصبحت في المستوى الطبيعي ولضمان المحافظة عليها ضمن المستوى الطبيعي.</p><p dir="RTL">قد يقرر طبيبك المعالج زيادة مقدار الجرعة المعطاة لك. وهذا يعني أنك الآن تتناول الجرعة الصحيحة والمناسبة لك من <strong>روزالِّس </strong>.</p><p dir="RTL"><strong>إذا تناولت روزالِّس &nbsp;بجرعة أكبر من الجرعة الموصى بها</strong></p><p dir="RTL">تحدث إلى طبيبك أو توجه إلى أقرب قسم طوارئ بالمستشفى للحصول على النصيحة.</p><p dir="RTL">في حال توجهك إلى المستشفى أو إذا كنت تتلقى علاجاً لحالة أخرى تعاني منها، يرجى منك إخبار<strong> </strong>الطاقم الطبي بأنك تتناول <strong>روزالِّس </strong>.</p><p dir="RTL"><strong>إذا سهوت عن تناول</strong> <strong>روزالِّس </strong></p><p dir="RTL">لا تقلق حيال ذلك الأمر، ما عليك إلا أن تتناول الجرعة التالية في الوقت الصحيح. لا تتناول جرعتين في آنٍ واحد لتعويض الجرعة التي قد سهوت عنها.</p><p dir="RTL"><strong>إذا توقفت عن تناول</strong> <strong>روزالِّس </strong></p><p dir="RTL">إذا كنت ترغب بالتوقف عن تناول <strong>روزالِّس ،</strong> فيرجى منك إخبار<strong> </strong>طبيبك المعالج بذلك. قد تعاود مستويات الكوليستيرول في الإرتفاع مجدداً في حال توقفك عن تناول <strong>روزالِّس </strong>.</p><p dir="RTL"><strong>إذا كان لديك أي أسئلة إضافية حول كيفية استخدام هذا الدواء، اسأل طبيبك المعالج أو الصيدلي الذي تتعامل معه.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي هذا الدواء إلى حدوث تأثيرات جانبية، ولكن على الرغم من ذلك لا تحدث لكل شخص.</p><p dir="RTL">من الضروري أن تكون على دراية كاملة حول&nbsp; التأثيرات الجانبية المحتمل حدوثها. &nbsp;عادة ما تكون هذه التأثيرات طفيفة و تختفي بعد فترة زمنية قصيرة.</p><p dir="RTL"><strong>توقف عن تناول </strong><strong>روزالِّس واطلب المساعدة الطبية على الفور</strong> في حال تعرضك لحدوث أي من التفاعلات التحسسية التالية:</p><p dir="RTL">&bull;&nbsp; صعوبة في التنفس مع أو بدون تورم في الوجه، الشفتين، اللسان و/أو الحلق.</p><p dir="RTL">&bull;&nbsp; تورم الوجه، الشفتين، اللسان و/أو الحلق، الأمر الذي قد يسبب صعوبة في البلع.</p><p dir="RTL">&bull;&nbsp; حكة جلدية شديدة (مع وجود تكتلات مرتفعة عن سطح الجلد)</p><p dir="RTL">&bull;&nbsp; ظهور بقع حمراء مسطحة شبيهة بالهدف أو دائرية الشكل على الجذع، غالباً ما يصاحب ذلك ظهور بثور مركزية، وتقشير الجلد، تقرحات في الفم، الحلق، الأنف، والأعضاء التناسلية والعينين. يمكن أن يسبق هذا الطفح الجلدي الخطير الحمى وأعراض تشبه أعراض الإنفلونزا (متلازمة ستيفن جونسون).</p><p dir="RTL">&bull;&nbsp; انتشار الطفح الجلدي في الجسم، ارتفاع شديد في درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة دريس أو متلازمة فرط الحساسية للأدوية).</p><p dir="RTL"><strong>كما يجب عليك أيضاً التوقف عن تناول روزالِّس و</strong><strong>إخبار </strong><strong>طبيبك المعالج على الفور في الحالات التالية: </strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>كنت قد تعرضت لحدوث</strong><strong> آلام غير معتادة </strong>في العضلات والتي تستمر لفترة أطول من المتوقع. إن التأثيرات الجانبية المتعلقة بالعضلات تعد الأكثر شيوعاً لدى فئة الأطفال والمراهقين مقارنة &nbsp;بالبالغين. كما هو عليه الحال مع الأدوية الأخرى التي تنتمي إلى مجموعة الستاتين، تعرض عدد قليل جداً من الأشخاص لتأثيرات جانبية غير مرغوب بها في العضلات و التي نادراً ما تطورت لتصبح تلف في العضلات المهدد للحياة &nbsp;تعرف بانحلال الربيدات.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>عانيت من حدوث تمزق في العضلات</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>عانيت من حدوث أعراض شبيهة بداء الذئبة الحمامية (بما في ذلك طفح جلدي، اضرابات في المفاصل وتأثيرات خلايا الدم الحمراء)</strong></p><p dir="RTL"><strong>التأثيرات </strong><strong>الجانبية الشائعة المحتملة (تصيب ما بين مريض واحد من كل 10 مرضى ومريض واحد من كل 100 مريض) </strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong>صداع ، ألم في المعدة، إمساك، شعور بالإعياء، ألم في العضلات، شعور بالضعف، دوخة.</p><p dir="RTL"><strong>&bull;&nbsp; </strong>ارتفاع نسبة البروتين في البول- عادة ما تعود إلى المعدل الطبيعي دون الحاجة إلى التوقف عن تناول الدواء (فقط تركيز 40 ملغم)</p><p dir="RTL"><strong>&bull;&nbsp; </strong>داء السكري- من المرجح حدوث ذلك إذا كنت تعاني من ارتفاع مستوى السكريات والدهون في الدم، إذا كنت تعاني من زيادة الوزن وارتفاع ضغط الدم. سوف يعمل طبيبك المعالج على مراقبتك أثناء تناولك هذا الدواء.</p><p dir="RTL"><strong>التأثيرات الجانبية الغير شائعة المحتملة (تصيب ما بين مريض واحد من كل 100 مريض &nbsp;ومريض واحد من كل 1000 مريض)</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong>طفح جلدي، حكة، أوأية تفاعلات جلدية أخرى.</p><p dir="RTL"><strong>&bull;&nbsp; </strong>ارتفاع نسبة البروتين في البول- عادة ما تعود إلى المعدل الطبيعي دون الحاجة إلى التوقف عن تناول الدواء (فقط تركيز 5 ملغم، 10ملغم، 20 ملغم).</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة المحتملة (تصيب ما بين مريض واحد من كل 1000 مريض ومريض واحد من كل 10.000 مريض)</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong>تفاعلات تحسسية حادة- تشتمل على عدة أعراض منها تورم الوجه، الشفتين، اللسان و/أو الحلق، صعوبة في التنفس والبلع، حكة جلدية شديدة (مع وجود تكتلات مرتفعة عن سطح الجلد). <strong>إذا كنت تعتقد بأنك تعاني من التفاعلات التحسسية، توقف عن تناول روزالِّس</strong> واطلب المساعدة الطبية على الفور.</p><p dir="RTL"><strong>&bull;&nbsp; </strong>تلف العضلات لدى البالغين- كإجراء احتياطي، <strong>توقف عن تناول روزالِّس واخبر طبيبك المعالج على الفور في حال تعرضك لآلام غير معتادة </strong>في العضلات والتي تستمر لفترة أطول مما كنت تتوقع.</p><p dir="RTL"><strong>&bull;&nbsp; </strong>ألم حاد في المعدة (التهاب البنكرياس)</p><p dir="RTL"><strong>&bull;&nbsp; </strong>ارتفاع مستوى إنزيمات الكبد في الدم</p><p dir="RTL"><strong>&bull;&nbsp; </strong>حدوث نزيف أو كدمات بصورة أسهل من المعتاد نتيجة لانخفاض مستوى الصفائح الدموية.</p><p dir="RTL"><strong>&bull;&nbsp; </strong>أعراض شبيهة بداء الذئبة الحمامية (بما في ذلك طفح جلدي، اضرابات في المفاصل وتأثيرات على خلايا الدم الحمراء).</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة جداً المحتملة (تصيب أقل من مريض واحد من كل 10.000 مريض)</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong>اليرقان (اصفرار الجلد و العينين)، التهاب الكبد، ظهور آثار دماء في البول، تلف أعصاب الساقين والذراعين (على سبيل المثال التنميل)، ألم في المفاصل، فقدان الذاكرة، تضخم أنسجة الثدي لدى الرجال (تثدي الرجل)</p><p dir="RTL"><strong>قد تتضمن التأثيرات الجانبية التي لا يعرف معدل تكرارها على:</strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong>&nbsp;الإسهال (براز رخو)، السعال، ضيق التنفس، وذمة ( تورم)، اضطرابات في النوم، بما في ذلك الأرق والكوابيس، صعوبات جنسية، اكتئاب، مشاكل في التنفس، بما في ذلك السعال المتواصل و/أو ضيق في التنفس أو الحمى، تضرر الأوتار، ضعف دائم في العضلات.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong></p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه، في حال حدوث أياً من التأثيرات الجانبية بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&middot;&nbsp; </strong><strong>المملكة </strong><strong>العربية</strong><strong> السعودية:</strong></p><p dir="RTL"><strong>&nbsp;المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">-&nbsp;&nbsp; <strong>رقم الفاكس: </strong>7662-205-11-966+</p><p dir="RTL">-&nbsp;&nbsp; <strong>مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL">-&nbsp;&nbsp; <strong>البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp; ا<strong>لموقع الإلكتروني:</strong> https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&middot;&nbsp; </strong><strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL">-&nbsp;&nbsp; الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن الإبلاغ عن التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp; </strong>يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL"><strong>-&nbsp; </strong>لا تستخدم <strong>روزالِّس </strong>&nbsp;بعد تاريخ انتهاء الصلاحية المذكور على الشريط والعلبة. يشير تاريخ الانتهاء إلى آخر يوم من الشهر المذكور.</p><p dir="RTL"><strong>-&nbsp; </strong>يحفظ في درجة حرارة أقل من 30&ordm;م.</p><p dir="RTL"><strong>-&nbsp; </strong>يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إن المادة الفعالة &nbsp;في روزالِّس هي: </strong><strong>روسوفاستاتين.</strong></p><p dir="RTL"><strong>يحتوي كل قرص مكسو على:</strong> &nbsp;روسوفاستاتين (على هيئة روسوفاستاتين الكالسيوم) 5 ملغم ، 10 ملغم، أو 20 ملغم.</p><p dir="RTL"><strong>المواد الأخرى:</strong> فوسفات الكالسيوم ثلاثية القاعدة، لاكتوز، سليلوز دقيق البلورات، كروس بوفيدون، استيارات المغنيسيوم، هيبروميلوز، تراي اسيتين، ثاني أكسيد التيتانيوم وأكسيد الحديد الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر أقراص <strong>روزالِّس </strong>&nbsp;5 ملغم، 10 ملغم ، و20 ملغم المكسوة في عبوات تحتوي كل منها على 28 قرصاً (4 أشرطة، يحتوي كل شريط على 7 أقراص) وعبوات تحتوي كل منها على 56 قرصاً (8 أشرطة، يحتوي كل شريط على 7 أقراص).</p><p dir="RTL">* قد لا يتم تسويق جميع أحجام العبوات الدوائية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الخليج للصناعات الدوائية &quot;جلفار&quot;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            م 9/2/2023 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosalus 20mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:

Item No. 	Material name	Scale (mg/Tablet)
		
	Active Ingredient:	
1.		Rosuvastatin Calcium *	20.790
	(equal to Rosuvastatin 20mg)	
		
	Inactive Ingredients:
For Core:	
1.		Tribasic calcium phosphate 	25.000
2.		Lactose spray dried 	111.000
3.		Microcrystalline cellulose 	120.410
4.		Crospovidone 	30.000
5.		Magnesium stearate 	2.800
		
	For Coating:	
1.		Hypromellose 	7.320
2.		Triacetin 	0.780
3.		Titanium dioxide 	1.620
4.		Iron oxide red	0.280
5.		Purified water **	q.s. 

Average weight of coated tablet is: 320 mg ± 3.0% (310.40 mg – 329.60 mg)
Note: 
*   20.790mg of Rosuvastatin Calcium is equivalent to 20mg of Rosuvastatin.
*  Based on Rosuvastation Calcium assay, the quantity of Microcrystalline cellulose may be varied to keep core tablet weight 310mg.
** This will not appear in the final product.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets
Description: Pink coloured, round, shallow, biconvex film-coated tablets
Face One: Debossed “R20”
Face Two: Plain 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment of hypercholesterolaemia</strong></p><p>&sect; Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p>&sect; Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p>&nbsp;</p><p><strong>Prevention of Cardiovascular Events</strong></p><p>&sect; Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.</p><p><strong>Rosalus</strong> may be given at any time of day, with or without food.</p><p><strong>Treatment of hypercholesterolaemia</strong></p><p>The recommended start dose is 5 or 10mg orally once daily in both statin na&iuml;ve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see section 5.1). In light of the increased reporting rate of adverse reactions with the 40mg dose compared to lower doses (see section 4.8), a final titration to the maximum dose of 40mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20mg, and in whom routine follow-up will be performed (see section 4.4). Specialist supervision is recommended when the 40mg dose is initiated.</p><p><strong>Prevention of cardiovascular events</strong></p><p>In the cardiovascular events risk reduction study, the dose used was 20mg daily (see section 5.1).</p><p><strong><u>Paediatric population</u></strong></p><p>Paediatric use should only be carried out by specialists.</p><p><strong>Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V)</strong></p><p><em><u>Heterozygous familial hypercholesterolaemia</u></em></p><p>In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5mg daily.</p><p>&sect; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.</p><p>&sect; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.</p><p>Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p><em><u>Homozygous familial hypercholesterolaemia</u></em></p><p>In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20mg once daily.</p><p>A starting dose of 5 to 10mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20mg once daily should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p>There is limited experience with doses other than 20mg in this population.</p><p>The 40mg tablet is not suitable for use in paediatric patients.</p><p><strong>Children younger than 6 years</strong></p><p>The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, <strong>Rosalus</strong> is not recommended for use in children younger than 6 years.</p><p><strong>Use in the elderly</strong></p><p>A start dose of 5mg is recommended in patients &gt;70 years (see section 4.4). No other dose adjustment is necessary in relation to age.</p><p><strong>Dosage in patients with renal insufficiency</strong></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5mg in patients with moderate renal impairment (creatinine clearance &lt;60 ml/min). The 40mg dose is contraindicated in patients with moderate renal impairment. The use of rosuvastatin in patients with severe renal impairment is contraindicated for all doses (see sections 4.3 and 5.2).</p><p><strong>Dosage in patients with hepatic impairment</strong></p><p>There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see section 5.2). In these patients an assessment of renal function should be considered (see section 4.4). There is no experience in subjects with Child-Pugh scores above 9. Rosuvastatin is contraindicated in patients with active liver disease (see section 4.3).</p><p><strong>Race</strong></p><p>Increased systemic exposure has been seen in Asian subjects (see sections 4.3, 4.4 and 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p><strong>Genetic polymorphisms</strong></p><p>Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of Rosuvastatin is recommended.</p><p><strong>Dosage in patients with pre-disposing factors to myopathy</strong></p><p>The recommended start dose is 5mg in patients with predisposing factors to myopathy (see section 4.4).</p><p>The 40mg dose is contraindicated in some of these patients (see section 4.3).</p><p><strong>Concomitant therapy </strong></p><p>Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when rosuvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir and/or tipranavir; see sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing rosuvastatin therapy. In situations where co-administration of these medicinal products with rosuvastatin is unavoidable, the benefit and the risk of concurrent treatment and rosuvastatin dosing adjustments should be carefully considered (see section 4.5).&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosuvastatin is contraindicated:
	In patients with hypersensitivity to rosuvastatin or to any of the excipients.
	In patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 times the upper limit of normal (ULN).
	In patients with severe renal impairment (creatinine clearance <30 ml/min).
	In patients with myopathy.
	in patients receiving concomitant combination of sofosbuvir/velpatasvir/voxilaprevir (see section 4.5)
	In patients receiving concomitant ciclosporin.
	During pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.
The 40mg dose is contraindicated in patients with pre-disposing factors for myopathy/ rhabdomyolysis. Such factors include:
	Moderate renal impairment (creatinine clearance < 60 ml/min)
	Hypothyroidism
	Personal or family history of hereditary muscular disorders
	Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate
	Alcohol abuse
	Situations where an increase in plasma levels may occur
	Asian patients
	Concomitant use of fibrates.
(See sections 4.4, 4.5 and 5.2)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Renal Effects</u></strong></p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of rosuvastatin, in particular 40mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the 40mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40mg.</p><p><strong><u>Skeletal Muscle Effects</u></strong></p><p>Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in rosuvastatin-treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded (see section 4.5) and caution should be exercised with their combined use. As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with rosuvastatin in post-marketing use is higher at the 40mg dose.</p><p><em>Creatine Kinase Measurement</em></p><p>Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.</p><p><em>Before Treatment</em></p><p>Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><p>&sect; Renal impairment</p><p>&sect; Hypothyroidism</p><p>&sect; Personal or family history of hereditary muscular disorders</p><p>&sect; Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate</p><p>&sect; Alcohol abuse</p><p>&sect; Age &gt;70 years</p><p>&sect; Situations where an increase in plasma levels may occur (see sections 4.2, 4.5 and 5.2)</p><p>&sect; Concomitant use of fibrates.</p><p>In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.</p><p><em>Whilst on Treatment</em></p><p>Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le;5xULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>In clinical trials, there was no evidence of increased skeletal muscle effects in the small number of patients dosed with rosuvastatin and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of rosuvastatin and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of Rosuvastatin with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.5 and 4.8).</p><p>Rosuvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of Rosuvastatin and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p>Rosuvastatin should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).</p><p><strong><u>Severe Cutaneous Adverse Reactions</u></strong></p><p>Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with rosuvastatin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of this reaction appear, rosuvastatin should be discontinued immediately and an alternative treatment should be considered.</p><p>If the patient has developed a serious reaction such as SJS or DRESS with the use of rosuvastatin, treatment with rosuvastatin must not be restarted in this patient at any time.</p><p><strong><u>Liver Effects </u></strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>As with other HMG-CoA reductase inhibitors, rosuvastatin should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p>It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose.</p><p>In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with rosuvastatin.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Race</u></strong></p><p>Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians (see sections 4.2, 4.3 and 5.2).</p><p><strong><u>Protease Inhibitors</u></strong></p><p>Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of rosuvastatin in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating Rosuvastatin doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of rosuvastatin is adjusted. (See sections 4.2 and 4.5).&nbsp;</p><p><strong><u>Lactose Intolerance</u></strong></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><strong><u>Interstitial Lung Disease</u></strong></p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long-term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p><strong><u>Diabetes Mellitus</u></strong></p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l.</p><p><strong><u>Paediatric Population</u></strong></p><p>The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 5.1).</p><p>In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Effect of co-administered medicinal products on rosuvastatin</u></strong></p><p><strong>Transporter protein inhibitors:</strong>&nbsp;Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of rosuvastatin with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see sections 4.2, 4.4 and 4.5 Table 1).</p><p><strong>Ciclosporin:</strong>&nbsp;During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). Rosuvastatin is contraindicated in patients receiving concomitant ciclosporin (see section 4.3). Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p><strong>Protease inhibitors:</strong>&nbsp;Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir/100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and C<sub>max</sub>&nbsp;respectively. The concomitant use of rosuvastatin and some protease inhibitor combinations may be considered after careful consideration of rosuvastatin dose adjustments based on the expected increase in rosuvastatin exposure (see sections 4.2, 4.4 and 4.5 Table 1).</p><p><strong>Gemfibrozil and other lipid-lowering products</strong>: Concomitant use of Rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin C<sub>max</sub>&nbsp;and AUC (see section 4.4).</p><p>Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1 g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.3 and 4.4). These patients should also start with the 5 mg dose.</p><p><strong>Ezetimibe:&nbsp;</strong>Concomitant use of 10mg rosuvastatin and 10 mg ezetimibe resulted in a 1.2-fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between Rosuvastatin and ezetimibe cannot be ruled out (see section 4.4).</p><p><strong>Antacid</strong>: The simultaneous dosing of Rosuvastatin with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after Rosuvastatin. The clinical relevance of this interaction has not been studied.</p><p><strong>Erythromycin:</strong>&nbsp;Concomitant use of Rosuvastatin and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in C<sub>max</sub>&nbsp;of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin.</p><p><strong>Ticagrelor: </strong>Ticagrelor might affect renal excretion of rosuvastatin, increasing the risk for rosuvastatin accumulation. Although the exact mechanism is not known, in some cases, concomitant use of ticagrelor and rosuvastatin led to renal function decrease, increased CPK level and rhabdomyolysis.</p><p><strong>Cytochrome P450 enzymes:</strong>&nbsp;Results from&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p><strong>Interactions requiring rosuvastatin dose adjustments (see also Table 1):</strong>&nbsp;When it is necessary to co-administer Rosuvastatin with other medicinal products known to increase exposure to rosuvastatin, doses of Rosuvastatin should be adjusted. Start with a 5 mg once daily dose of Rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of Rosuvastatin should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of Rosuvastatin taken without interacting medicinal products, for example a 20 mg dose of Rosuvastatin with gemfibrozil (1.9-fold increase), and a 10 mg dose of Rosuvastatin with combination ritonavir/atazanavir (3.1-fold increase).</p><p>If medicinal product is observed to increase rosuvastatin AUC less than 2-fold, the starting dose need not be decreased but caution should be taken if increasing the Crestor dose above 20mg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:570px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>2-fold or greater than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days</p></td><td style="vertical-align:top"><p>10mg single dose</p></td><td style="vertical-align:top"><p>7.4 -fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months</p></td><td style="vertical-align:top"><p>10 mg OD, 10 days</p></td><td style="vertical-align:top"><p>7.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darolutamide 600 mg BID, 5 days</p></td><td style="vertical-align:top"><p>5mg, single dose</p></td><td style="vertical-align:top"><p>5.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Regorafenib 160 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>3.8-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 300 mg/ritonavir 100 mg OD, 8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>3.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Velpatasvir 100 mg OD</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.7-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ombitasvir 25 mg/paritaprevir 150 mg/ Ritonavir 100 mg OD/ dasabuvir 400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>2.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Teriflunomide</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>2.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Grazoprevir 200 mg/elbasvir 50 mg OD, 11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.3-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Glecaprevir 400 mg/pibrentasvir 120 mg OD, 7 days</p></td><td style="vertical-align:top"><p>5 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg/ritonavir 100 mg BID, 17 days</p></td><td style="vertical-align:top"><p>20 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Capmatinib 400mg BID</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Fostamatinib 100 mg twice daily</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2.0-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Febuxostat 120 mg OD</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Less than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen </strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eltrombopag 75 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 600 mg/ritonavir 100 mg BID, 7 days</p></td><td style="vertical-align:top"><p>10 mg OD, 7 days</p></td><td style="vertical-align:top"><p>1.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg/ritonavir 200 mg BID, 11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone 400 mg BID</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>**1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>**1.2-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Decrease in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen </strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>20% &darr;</p></td></tr><tr><td style="vertical-align:top"><p>Baicalin 50 mg TID, 14 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>47% &darr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone. Data given as % change represent % difference relative to rosuvastatin alone.</p><p>Increase is indicated as &ldquo;&uarr;<u>&rdquo;,</u>&nbsp;decrease as &ldquo;&darr;&rdquo;.</p><p>**Several interaction studies have been performed at different rosuvastatin dosages, the table shows the most significant ratio</p><p>AUC = area under curve; OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily</p></td></tr></tbody></table><p>The following medical product/combinations did not have a clinically significant effect on the AUC ratio of rosuvastatin at coadministration:</p><p>Aleglitazar 0.3 mg 7 days dosing; Fenofibrate 67 mg 7 days TID dosing; Fluconazole 200mg 11 days OD dosing; Fosamprenavir 700 mg/ritonavir 100 mg 8 days BID dosing; Ketoconazole 200 mg 7 days BID dosing; Rifampin 450 mg 7 days OD dosing; Silymarin 140 mg 5 days TID dosing.<strong><u> </u></strong></p><p><strong><u>Effect of rosuvastatin on co-administered medicinal products</u></strong></p><p><strong>Vitamin K antagonists:&nbsp;</strong>As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of Rosuvastatin in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of Rosuvastatin may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p><strong>Oral contraceptive/hormone replacement therapy (HRT):&nbsp;</strong>Concomitant use of Rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant Rosuvastatin and HRT, therefore, a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p><strong>Other medicinal products:</strong></p><p><u>Digoxin:</u>&nbsp;Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.</p><p><u>Fusidic Acid:</u>&nbsp;Interaction studies with rosuvastatin and fusidic acid have not been conducted. The risk of myopathy, including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>If treatment with systemic fusidic acid is necessary, Rosuvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment.&nbsp;<strong>Also see section 4.4.</strong></p><p><strong>Paediatric population:&nbsp;</strong>Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rosuvastatin is contraindicated in pregnancy and lactation.</p><p>Women of child bearing potential should use appropriate contraceptive measures.</p><p>Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see section 5.3). If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of rosuvastatin on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, rosuvastatin is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of Rosuvastatin-treated patients were withdrawn due to adverse reactions.</p><p><strong><u>Tabulated list of adverse reactions </u></strong></p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p><strong>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Endocrine disorders</em></p></td><td style="vertical-align:top"><p>Diabetes mellitus<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Polyneuropathy</p><p>Memory loss</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p><p>Sleep disturbances (including insomnia and nightmares)</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cough</p><p>Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastro-intestinal disorders</em></p></td><td style="vertical-align:top"><p>Constipation</p><p>Nausea</p><p>Abdominal pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Increased hepatic transaminases</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p><p>Drug reaction with eosinophilia</p><p>and systemic</p><p>symptoms</p><p>(DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculo-skeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Myopathy (including myositis)</p><p>Rhabdomyolysis</p><p>Lupus-like syndrome</p><p>Muscle rupture</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Tendon disorders, sometimes complicated by rupture</p><p>Immune-mediated necrotising myopathy</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1&nbsp;</sup>Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p></td></tr></tbody></table><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p><strong>Renal effects:&nbsp;</strong>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with Rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with Rosuvastatin and clinical trial data show that the occurrence is low.</p><p><strong>Skeletal muscle effects:&nbsp;</strong>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in Rosuvastatin-treated patients with all doses and in particular with doses &gt; 20 mg.</p><p>A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see section 4.4).</p><p><strong>Liver effects:&nbsp;</strong>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>The following adverse events have been reported with some statins:</p><p><em>Sexual dysfunction.</em></p><p>Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p><strong>Paediatric population:</strong>&nbsp;Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults (see section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p><strong><u>&nbsp;</u></strong></p><p>&nbsp;</p><p><strong><u>Healthcare professionals are asked to report any suspected adverse reactions via:</u></strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fax</strong><strong>: </strong>+966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>SFDA Call Centre: </strong>19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Website: </strong>https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:&nbsp;</strong>HMG-CoA reductase inhibitors</p><p><strong>ATC code:&nbsp;</strong>C10AA07</p><p><strong><u>Mechanism of action</u></strong></p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Rosuvastatin reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, non-HDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 3). Rosuvastatin also lowers the LDL-C/HDL-C, total C/HDL-C and non-HDL-C/HDL-C and the ApoB/ApoA-I ratios.</p><p><strong>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Total-C</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p></td><td style="vertical-align:top"><p><strong>nonHDL-C</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p></td><td style="vertical-align:top"><p><strong>ApoA-I</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-35</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-52</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-10</p></td><td style="vertical-align:top"><p>-48</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-55</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>-51</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>-63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-28</p></td><td style="vertical-align:top"><p>-60</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>Rosuvastatin is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, regardless of race, sex or age and in special populations such as diabetics or patients with familial hypercholesterolaemia.</p><p>From pooled phase III data, Rosuvastatin has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/L) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/L).</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given Rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. Thirty-three percent (33%) of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/L).</p><p>In a force-titration, open label trial, 42 patients (including 8 paediatric patients) with homozygous familial hypercholesterolaemia were evaluated for their response to Rosuvastatin 20 &ndash; 40 mg. In the overall population, the mean LDL-C reduction was 22%.</p><p>In clinical studies with a limited number of patients, Rosuvastatin has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin (see section 4.4).</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/L (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of Rosuvastatin 40 mg. The 40 mg dose should only be prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk (see section 4.2).</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total mortality was unchanged in this high-risk group (p=0.193). In a post-hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to include subjects above 65 yrs) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total mortality was unchanged in this high-risk group (p=0.076).</p><p>In the JUPITER trial, there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medication due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin, 6.6% placebo).</p><p><strong>&nbsp;</strong></p><p><strong>Paediatric population</strong></p><p>In a double-blind, randomised, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10 to 17 years of age (Tanner stage II-V, females at least 1-year post-menarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10 to 13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/L.</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug events.</p><p>Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.</p><p>After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, Month 24: 124 mg/dL) and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively.</p><p>Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL C/HDL-C, ApoB, ApoB/ApoA-1. These changes were each in the direction of improved lipid responses and were sustained over 2 years.</p><p>No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see section 4.4).</p><p>Rosuvastatin was studied in a randomised, double-blind, placebo-controlled, multi-centre, cross-over study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to 17 years) with homozygous familial hypercholesterolaemia. The study included an active 4-week dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed by a 6-week placebo treatment period, and a 12-week maintenance phase during which all patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or apheresis therapy continued the treatment throughout the entire study.</p><p>A statistically significant (p=0.005) reduction in LDL-C (22.3%, 85.4 mg/dL or 2.2 mmol/L) was observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically significant reductions in Total-C (20.1%, p=0.003), non-HDL-C (22.9%, p=0.003) and ApoB (17.1%, p=0.024) were observed. Reductions were also seen in TG, LDL-C/HDL-C, Total-C/HDL-C, non-HDL-C/HDL-C and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks of continuous therapy. One patient had a further reduction in LDL-C (8.0%), Total-C (6.7%) and non-HDL-C (7.4%) following 6 weeks of treatment with 40 mg after up-titration.</p><p>During an extended open-label treatment in 9 of these patients with 20 mg rosuvastatin for up to 90 weeks, the LDL-C reduction was maintained in the range of -12.1% to -21.3%.</p><p>In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the force-titration open label study with homozygous familial hypercholesterolaemia (see above), the percent reduction in LDL-C (21.0%), Total-C (19.2%) and non-HDL-C (21.0%) from baseline following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the aforementioned study in children and adolescents with homozygous familial hypercholesterolaemia.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong>&nbsp;Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p><strong>Distribution</strong>: Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p><strong>Metabolism:</strong>&nbsp;Rosuvastatin undergoes limited metabolism (approximately 10%).&nbsp;<em>In vitro</em>&nbsp;metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p><strong>Excretion:</strong>&nbsp;Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p><strong>Linearity:</strong>&nbsp;Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.</p><p><strong><u>Special populations:</u></strong></p><p><strong>Age and sex:&nbsp;</strong>There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The exposure in children and adolescents with heterozygous familial hypercholesterolemia appears to be similar to or lower than that in adult patients with dyslipidaemia (see &ldquo;Paediatric population&rdquo; below).</p><p><strong>Race:</strong>&nbsp;Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and C<sub>max</sub>&nbsp;in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.</p><p><strong>Renal insufficiency:</strong>&nbsp;In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N-desmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.</p><p><strong>Hepatic insufficiency:</strong>&nbsp;In a study with subjects with varying degrees of hepatic impairment, there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p><strong>Genetic polymorphisms:</strong>&nbsp;Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of rosuvastatin is recommended.</p><p><strong>Paediatric population:</strong>&nbsp;Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolaemia 10 to 17 or 6 to 17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses, where systemic exposures were several times above the therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p><p><strong><u>For Core:</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Tribasic calcium phosphate</p></td></tr><tr><td style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Lactose spray dried</p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p></td></tr><tr><td style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Crospovidone</p></td></tr><tr><td style="vertical-align:top"><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>For Coating:</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose</p></td></tr><tr><td style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Triacetin</p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide</p></td></tr><tr><td style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Iron oxide red</p></td></tr><tr><td style="vertical-align:top"><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Purified water **</p></td></tr></tbody></table><p><strong><u>Note: </u></strong></p><p>** This will not appear in the final product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; <strong>Pack of 28 Tablets: </strong>4x7&rsquo;s Tablets in an Alu-Alu blister packed in a printed box, along with a leaflet.</p><p>&sect; <strong>Pack of 56 Tablets:</strong> 8x7&rsquo;s Tablets in an Alu-Alu blister packed in a printed box, along with a leaflet.</p><p>&nbsp;</p><p>* Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09. February. 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>